ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
ORIC Pharmaceuticals (Nasdaq: ORIC) granted equity awards under Nasdaq Rule 5635(c)(4) to two new non-executive employees who started in May 2026. On June 1, 2026, they received 34,800 stock options and 5,900 RSUs under the 2022 Inducement Equity Incentive Plan, with multi-year vesting schedules tied to continued employment.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
ORIC was up 2.3% while key biotech peers like NUVB, MAZE, RAPP, and ELVN traded lower and only one scanned peer (WVE, up 3.14%) showed upside momentum, indicating stock-specific rather than sector-driven action.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 27 | Investor conferences | Neutral | -1.5% | Participation in June 2026 healthcare investor conferences and 1x1 meetings. |
| May 4 | Earnings and updates | Positive | -0.6% | Q1 2026 results, strong cash position, and Phase 3/1b program updates. |
| May 1 | Inducement grants | Neutral | -1.4% | Equity inducement awards to new hires under the 2022 plan. |
| Apr 17 | Preclinical data | Positive | +1.3% | AACR posters showing supportive preclinical data for rinzimetostat. |
| Apr 3 | Inducement grants | Neutral | +0.2% | Inducement equity awards to a new non-executive employee. |
Recent news spans clinical data, earnings, conferences, and recurring inducement grants. Positive clinical and financial updates have shown mixed price reactions, with one aligned move and one mild selloff after good news, suggesting no consistent pattern yet.
Over recent months, ORIC has highlighted progress in oncology programs and corporate activity. In April 2026, preclinical data for rinzimetostat at AACR coincided with a 1.3% gain, while multiple inducement grant announcements on Apr 1 and May 1 saw minimal price impact. Q1 2026 earnings and operational updates on May 4 and investor conference participation on May 27 both saw modest negative moves. Today’s inducement grants fit into this ongoing pattern of routine equity awards linked to new hires.
Market Pulse Summary
This announcement details routine inducement equity awards—34,800 non-qualified stock options and 5,900 RSUs—granted to new employees under ORIC’s 2022 Inducement Equity Incentive Plan pursuant to Nasdaq Rule 5635(c)(4). It underscores ongoing hiring but involves a relatively small share count versus the company’s $830.21M market capitalization. Investors may watch future filings for larger equity plans, as well as upcoming clinical and financial updates, to gauge longer-term dilution and growth dynamics.
Key Terms
non-qualified stock options financial
restricted stock units financial
nasdaq rule 5635(c)(4) regulatory
exercise price financial
vesting financial
equity incentive plan financial
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.
These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date. Twenty-five percent (
The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain penetrant inhibitor targeting EGFR exon 20 and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC’s product candidates; the potential advantages of ORIC’s product candidates; and plans underlying ORIC’s clinical trials and development. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC’s product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on May 4, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
